Spectral Diagnostics Profit Margin 2006-2019 | EDTXF
Current and historical gross margin, operating margin and net profit margin for Spectral Diagnostics (EDTXF) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Spectral Diagnostics net profit margin as of September 30, 2019 is -75.49%.
|Spectral Diagnostics Annual Profit Margins
|Spectral Diagnostics Quarterly Profit Margins
||Medical Instruments Manufacturing
Spectral Medical Inc. develops and commercializes theranostic treatment for severe sepsis. The company's products include Endotoxin Activity Assay, a rapid diagnostic test for detection of components of gram negative bacterial cell wall; and Toraymyxin, a therapeutic hemoperfusion device for the treatment of sepsis that removes endotoxin from the bloodstream. Spectral Medical Inc., formerly known as Spectral Diagnostics Inc., is headquartered in Toronto, Canada.